Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
The registered capital of the newly founded company is € 50 million
Signs MoU with the Govt. of Gujarat at Vibrant Gujarat Summit
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
Receives registration of Valganciclovir powder for oral solution in Germany
Fischer Chemic will make an entry into the growing market of diagnostic imaging industry with innovative and disruptive technologies
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Subscribe To Our Newsletter & Stay Updated
